DENVER, CO, April 2 /CNW Telbec/ - Medical International Technology Inc.
(MDLH. PK) (http://www.mitcanada.ca http://www.mitinvest.ca), is pleased to
announce that it has obtained another US patent from the United States Patent
and Trademark Office for its Needle-Free Jet-Injector. Other similar
international patents are pending. "MIT" is pleased to obtain this patent for
it will help the company enter the biggest world market using a unique
low-pressure Needle-free technology. This technology offers a front-line means
of prevention against pandemics, contributes to eliminate the possibility of
both pre-injection contamination and post-injection cross-infection from
needles/syringes, increases institutional sanitation, and protects human
health. This patent reinforces the validity and recognition of our technology.
This technology is the outcome of more than twenty-eight years of
research and development and the driving force behind the Med-Jet(R) product
line for humans and the Agro-Jet(R) product line for animals.
"MIT" is consolidating its efforts, strengthening its team, reorganizing
its marketing / sales departments and financial bases in anticipation of its
Medical International Technology Inc. is pleased to continue providing a
safe and effective means to help prevent the spread of deadly diseases to both
humans and animals through the use of the Med-Jet(R) and Agro-Jet(R)
Needle-Free injection system.
Karim Menassa, President
On Behalf of the Board of Directors
About Medical International Technology, Inc. MIT CANADA, with offices in
Montreal, is a subsidiary of Denver, Colorado-based Medical International
Technology, Inc. (MIT USA), which specializes in the development, production,
marketing and sale of needle-free injectors both for humans and animals, for
individual and mass vaccinations.
The statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties, including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development and acquisition of new product lines and services, government
approval processes, the impact of competitive products or pricing a
technological changes, the effect of economic conditions and other
uncertainties, and the risk factors set forth from time to time in the
Company's SEC reports, including but not limited to its annual report on Form
10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K.
Medical International Technology Inc. takes no obligation to update or correct
For further information:
For further information: Karim Menassa, President, (514) 339-9355,
email@example.com; www.mitcanada.ca, www.mitinvest.ca